Jeffrey Friedland Joins OWC Pharmaceutical Research's Advisory Board

The Noted Author and Industry Keynote Speaker To Serve As Company's U.S. Representative

Mar 15, 2016, 08:08 ET from OWC Pharmaceutical Research Corp.

PETACH TIKVA, Israel, March 15, 2016 /PRNewswire/ --

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that Jeffrey Friedland has joined the Company's Advisory Board. In addition to advising OWC on its business development efforts, Mr. Friedland will serve as the Company's U.S. representative.

     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )

     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )

Jeffrey Friedland is an emerging market pioneer and thought leader. His firm, Friedland Global Capital, was one of the first American investment banks to establish a presence in China, and he can now be found on the forefront of the cannabis movement, where is activities include:

  • He is CEO of INTIVA Inc., a multi-faceted life sciences company with a focus on the worldwide legal cannabis industry. INTIVA has established operating businesses and made venture investments in the cannabis industry in California, Colorado, Canada and Israel.  
  • His book, Marijuana, the World's Most Misunderstood Plant, Mr. Friedland dives into the world of medical marijuana, discussing what we know and what we still hope to discover.
  • He is an owner of two retail cannabis stores in Colorado, which are located in the mountain resort towns of Breckenridge and Crested Butte, and a cannabis cultivation facility located south of Steamboat Springs, which was featured in CNN's 2015 reality series, High Profits.

Mordechai Bignitz, OWCP Chairman and CEO, commented on the appointment, "Jeffrey is an active investor and advisor to the cannabis sector, bringing a wealth of knowledge and insight to OWC Pharmaceuticals. His experience in both the cannabis and financial markets will be invaluable as we work to commercialize our proprietary products and technologies."

"I have been involved with many ventures in the medical marijuana industry; however, one of my biggest concerns has been the lack of oversight, particularly in the U.S., where the federal government has made research all but impossible." Mr. Friedland went on to say "Because OWC Pharmaceutical is headquartered in Israel, where cannabis research is not only allowed, but encouraged, they have been able to implement a research and development program of the caliber associated with the pharmaceutical industry. I believe this approach provides OWC Pharmaceutical with a significant competitive advantage and I look forward to working with the Company in their effort to advance the medical use of cannabis."

In addition to his work in the cannabis sector, Mr. Friedland is the CEO of Friedland Global Capital, which provides corporate finance and strategic advisory services to entrepreneurial companies in emerging markets. He has been the CEO of a Nasdaq-listed company, a member of the board of directors and chairman of the audit committee of a New York Stock Exchange-listed company, and the chairman of the supervisory board of a company listed on the Regulated Market of the Frankfurt Stock Exchange. Mr. Friedland has been featured, interviewed or quoted in numerous publications including the Wall Street Journal, USA Today, The South China Morning Post (Hong Kong), NBC.com, Forbes, CNBC and its predecessor, Financial News Network, Bloomberg Information Radio, and Bloomberg TV. This is the second book he has written. All Roads Lead to China: An Investor Road Map to the World's Fastest Growing Economy was published in 2014.

About OWC Pharmaceutical Research Corp.    

OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB: OWCP).  For more information, visit: http://www.owcpharma.com/

Notice Regarding Forward-Looking Statements   

This press release may contain forward-looking statements, about OWC's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, OWC or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by OWC with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of OWC's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause OWC's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause OWC's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in OWC's filings with the SEC. In addition, OWC operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. OWC does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors associated with an investment in our securities which are included in our Registration Statement on Form S-1 as filed with the U.S. Securities and Exchange Commission on February 16, 2016.

Contact Information:
In Israel:

Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659

In the United States: 
Jeffrey Friedland
Email: Jfriedland@owcpharma.com
Tel: +1-(646)-450-8909


SOURCE OWC Pharmaceutical Research Corp.